Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia

Anand Jillella, R. Doria, K. Khan, D. Zelterman, Y. H. Ahmad, B. R. Smith, W. Holmes, P. Becker, K. B. Roberts, J. M. Rappeport

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.

Original languageEnglish (US)
Pages (from-to)1095-1100
Number of pages6
JournalBone Marrow Transplantation
Volume23
Issue number11
DOIs
StatePublished - Jan 1 1999

Fingerprint

Whole-Body Irradiation
Cytarabine
Homologous Transplantation
Bone Marrow Transplantation
Cyclophosphamide
Leukemia
Hematologic Neoplasms
Recurrence
Kaplan-Meier Estimate
Graft vs Host Disease
Methotrexate
Cyclosporine
Diarrhea
Bone Marrow
Prospective Studies
Confidence Intervals
Survival

Keywords

  • Bone marrow transplant
  • Cyclophosphamide
  • Leukemia
  • Myeloablation
  • Preparative regimen
  • Veno-occlusive disease
  • ara-C

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. / Jillella, Anand; Doria, R.; Khan, K.; Zelterman, D.; Ahmad, Y. H.; Smith, B. R.; Holmes, W.; Becker, P.; Roberts, K. B.; Rappeport, J. M.

In: Bone Marrow Transplantation, Vol. 23, No. 11, 01.01.1999, p. 1095-1100.

Research output: Contribution to journalArticle

Jillella, A, Doria, R, Khan, K, Zelterman, D, Ahmad, YH, Smith, BR, Holmes, W, Becker, P, Roberts, KB & Rappeport, JM 1999, 'Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia', Bone Marrow Transplantation, vol. 23, no. 11, pp. 1095-1100. https://doi.org/10.1038/sj.bmt.1701786
Jillella, Anand ; Doria, R. ; Khan, K. ; Zelterman, D. ; Ahmad, Y. H. ; Smith, B. R. ; Holmes, W. ; Becker, P. ; Roberts, K. B. ; Rappeport, J. M. / Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. In: Bone Marrow Transplantation. 1999 ; Vol. 23, No. 11. pp. 1095-1100.
@article{b7e7cb8de2a84ad5aacbd29017fc02f8,
title = "Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia",
abstract = "This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69{\%} (58-82) and at 5 years was 54{\%} (42-69) with the numbers in parentheses representing the 95{\%} confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53{\%}) patients are alive without evidence of disease. Only four of the 58 patients (7{\%}) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7{\%} with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.",
keywords = "Bone marrow transplant, Cyclophosphamide, Leukemia, Myeloablation, Preparative regimen, Veno-occlusive disease, ara-C",
author = "Anand Jillella and R. Doria and K. Khan and D. Zelterman and Ahmad, {Y. H.} and Smith, {B. R.} and W. Holmes and P. Becker and Roberts, {K. B.} and Rappeport, {J. M.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701786",
language = "English (US)",
volume = "23",
pages = "1095--1100",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia

AU - Jillella, Anand

AU - Doria, R.

AU - Khan, K.

AU - Zelterman, D.

AU - Ahmad, Y. H.

AU - Smith, B. R.

AU - Holmes, W.

AU - Becker, P.

AU - Roberts, K. B.

AU - Rappeport, J. M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.

AB - This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.

KW - Bone marrow transplant

KW - Cyclophosphamide

KW - Leukemia

KW - Myeloablation

KW - Preparative regimen

KW - Veno-occlusive disease

KW - ara-C

UR - http://www.scopus.com/inward/record.url?scp=0032972923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032972923&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701786

DO - 10.1038/sj.bmt.1701786

M3 - Article

C2 - 10382947

AN - SCOPUS:0032972923

VL - 23

SP - 1095

EP - 1100

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -